News Article | March 1, 2017
Global OrthoBiologic has built a comprehensive network of experts in Europe, South America, Middle East, Asia, and Australia. The company partners with recognized medical facilities worldwide for evidence-based clinical medicine. Global OrthoBiologic’s subsidiary, Global MED ACADEMY, provides educational events allowing physicians and healthcare practitioners to expand their knowledge of best practices and clinical applications of regenerative medicine. Global MED ACADEMY provides world class training workshops consisting of lectures and hands-on practicum to mentor physicians and healthcare professionals in best practices and standardized methods for optimal results and better patient outcomes. Additionally, larger international conferences are provided in various locations to provide opportunities for physicians to learn new information and relevant protocols that impact their work while creating an occasion for networking with highly respected and esteemed international thought leaders with clinical experience in a variety of specialties. Educational information is provided to physicians both at sponsored events as well as through Global MED ACADEMY’s digital websites, physician portal, newsletters, email content, and social media. Randy Beimel (GOB President). “The Global MED ACADEMY international network contains thought-leaders within the regenerative medicine industry from all the major countries in the world. Additionally, as social media spreads information about Global MED ACADEMY, the impact of marketing continues to attract many to Global MED ACADEMY which facilitates a steady stream of new collaborations.” Global MED ACADEMY has a vast international network within the regenerative medicine community that includes physicians, scientists, academics, and clinics. Global MED ACADEMY has developed, with its Scientific Advisory board, specially dedicated protocols for Regenerative Medicine treatments. The physicians within the Global MED ACADEMY network represent multiple specialties, including plastic surgeons, gynecologists, urologists, aesthetics and aesthetic gynecologist, orthopedic and sports medicine, wound healing, neurological, and health and well-being specialists, to name a few. Membership in Global MED ACADEMY is available for healthcare professionals interested in up-to-date information about novel therapies, innovative technology, specialized protocols and best clinical translation practices.Global MED ACADEMY provides access for its membership and those within the healthcare industry to participate in events focused on cutting edge procedures. The members’ results from the Global MED ACADEMY protocols will be included in clinical studies published in worldwide recognized Medical Journals. Global MED ACADEMY collaborates with educational institutes, regenerative medicine companies and governmental bodies to globally impact patients through its Medical Tourism subsidiary, allowing them to live a better quality of life as they advance in years. Dr. Dzihan Abazovic (GOB Scientific Officer). “As medical discoveries rapidly advance, it is difficult for practicing physicians to keep up with the flood of information. For that reason, Global MED ACADEMY offers regularly scheduled courses and workshops focused on training and mentoring physicians interested in offering evidence-based medicine and therapeutic choices to their patients.” Mihail Blagoev (GOB VP International Business Development). “The Global MED ACADEMY goal is to bring to doctors all over the world an education and training experience that allows them to incorporate cutting edge procedures, techniques, products and technologies into their everyday practice and to be recognized as leaders in the exciting field of Regenerative Medicine.” About Global OrthoBiologic (GOB) Global OrthoBiologic, based in Miami Florida, invests, identifies, develops and markets ground-breaking medical technologies related to Regenerative Medicine in the global market. Global OrthoBiologic is a privately-held medical technologies company specializing in therapies that significantly enhance the body’s natural healing ability. The company has developed extensive experience in the most advanced medical device industries. In the past several years, the emphasis has been focused exclusively on Regenerative Medicine and stem cell technologies, products, and therapies. The technologies for stem cells are cutting edge, safe, clean and do not use any additives, enzymes, or require culturing or growing of cells. Global OrthoBiologic consults with medical technology companies that are startups and/or companies looking to expand and grow their business. Global OrthoBiologic has built a comprehensive network of experts in Europe, South America, Middle East, Asia, and Australia. The company partners with recognized medical facilities worldwide for evidence-based clinical medicine. Global OrthoBiologic has additional sales offices in Sofia, Bulgaria and Dubai, UAE, as well as a distribution center in Amsterdam, Netherlands.
News Article | February 15, 2017
WASHINGTON, DC--(Marketwired - Feb 14, 2017) - The National Academies of Sciences, Engineering and Medicine today issued a report that examines the scientific, clinical, ethical, legal and social implications of human genome editing. The Alliance for Regenerative Medicine (ARM) believes that genomic medicines, including genome editing, hold great promise for the treatment of a multitude of hereditary and acquired diseases where there is presently no effective treatment available. The Alliance for Regenerative Medicine (ARM) applauds the National Academies of Sciences, Engineering and Medicine for its very thorough and thoughtful report on the current scientific, technical, ethical, and policy issues relating to human genome editing. We support the need for responsible and ethically appropriate approaches to research and clinical use of these technologies following the seven guiding principles outlined in the report, as well as the need for continued public engagement and dialogue. We also commend the Academies for recognizing the profound impact genome editing will have on the development of a new class of medicines for many patients with presently incurable diseases. We believe the report's recommendations that "existing regulatory infrastructure and processes for reviewing and evaluating somatic gene therapy to treat or prevent disease and disability" are sensible and will help create a safe path toward eventual clinical adoption and regulatory approval of therapeutics based on somatic cell genome editing. In addition, we note the report's recommendations on heritable germline genome editing and the strict criteria to be met before ever considering clinical study. ARM will continue to monitor developments related to these applications, but until safety is proven and the risks associated with long-term consequences, both intended and unintended, are fully evaluated, we will remain solely focused on realizing the full therapeutic potential of somatic cell genome editing. Further, we must be satisfied that all relevant moral and ethical issues have been addressed and that a broad societal consensus exists as to the benefits and risks associated with editing the germline. ARM believes that advances in the field of gene therapy, including somatic cell genome editing, have the potential to profoundly and positively impact the practice of medicine for currently incurable genetic diseases, such as muscular dystrophy, sickle cell disease (SCD), cystic fibrosis, hemophilia, adrenoleukodystrophy (ALD), Alpha-1 Antitrypsis Deficiency (AATD), and Transthyretin Amyloidosis (ATTR), as well as acquired diseases such as cancer, certain forms of heart disease, HIV, Hepatitis B virus, and other infectious diseases. It is estimated that 30 million Americans, or 1 in every 10 people, are afflicted with one of the approximately 7,000 rare diseases. Two thirds of those affected are children. The National Organization for Rare Disorders (NORD) estimates that for 95 percent of these diseases no FDA-approved treatment currently exists,(1) and the few treatments that are available generally address the symptoms and not the underlying genetic cause of the disease. As a result, these treatments must be administered for the duration of a patient's life. In contrast, genome editing offers the very real potential to bring hope to rare disease patients through development of a broad range of new technologies to precisely target and modify the genetic material of a patient's cells. By removing, repairing, or replacing a defective gene or genes, these therapies hold the promise of potentially curing a broad range of diseases with a single treatment. Similarly, in diseases such as cancer, HIV, and beta-thalessemia, genome editing is being employed to modify T cells and hematopoietic stem cells ex-vivo. The modified cells are then delivered to the patient to treat and potentially cure the underlying disease. These programs build upon early successes and several advanced programs based on somatic cell gene replacement therapies. According to a recent white paper titled, "Therapeutic Gene Editing," published by the American Society of Gene & Cell Therapy (ASGCT), "the successful development of effective treatments based on genome editing could shift today's approach from a lifetime of symptom management for hereditary diseases to tomorrow's ideal of making a one-time curative repair or change to an individual's affected gene. The goal is a long lasting, perhaps life-long effect that minimizes or even eliminates disease."(2) Diseases involving multiple genes may also be treatable if the therapy can alter specific genes affecting the course of the disease. ARM represents a number of companies and research institutions that use various gene therapy and genome editing technology platforms, including CRISPR/Cas9, zinc finger nucleases (ZFNs), homing endonucleases, vector-driven homologous recombination, transcription activator-like effector-based nucleases (TALEN) and meganucleases, amongst others to design therapeutics that address a wide range of, hereditary and acquired diseases. About The Alliance for Regenerative Medicine The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 250 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org. 1. National Organization for Rare Disorders (2015). NORD developing 20 natural history studies for 20 rare diseases (Press Release). https://rarediseases.org/fda-awards-nord-250000-grant-to-support-the-development-of-20-natural-history-studies-for-rare- disease-research/. 2. American Society of Gene & Cell Therapy (2016). Therapeutic Gene Editing: An American Society of Gene & Cell Therapy White Paper. http://www.asgct.org/UserFiles/file/TherapeuticGeneEditingWP_Nov21_v1.pdf.
News Article | February 22, 2017
In a study led by Barbara Driscoll, PhD, of The Saban Research Institute of Children's Hospital Los Angeles, researchers demonstrate, for the first time that inhaled resveratrol treatments slow aging-related degenerative changes in mouse lung. Lung aging, characterized by airspace enlargement and decreasing lung function, is a significant risk factor for chronic human lung diseases. The study is published online in the journal Thorax. "We believe that ours is the first study to demonstrate a beneficial effect of lung-directed resveratrol treatments on aging lung function," said Driscoll. Resveratrol (RSL), a chemical found in red wine, is an antimicrobial chemical substance produced by plants to protect against infection and stress-related changes. It has previously been shown to support muscle metabolism when delivered orally. RSL prophylaxis by inhalation was a novel measure taken by the research team as a potential approach for slowing age-related deterioration of lung function and structure by preserving alveolar epithelial type 2 cells (AEC2) which line alveoli (the tiny air sacs in the lungs through which the exchange of oxygen and carbon dioxide takes place) and produce surfactant which is vital for efficient breathing. In healthy young adults, breathing is an essential, efficient process, but natural aging of the lung occurs at a steady and irreversible rate, as measured by a decline in lung function. This natural deterioration leads to a significantly reduced quality of life, over a time frame dependent on genetic and environmental factors. Although some available therapies can ameliorate symptoms, aging-related lung failure is generally irreversible and is accompanied by high rates of morbidity and mortality due to increased disease risk, including development of COPD, with accompanying emphysema and chronic bronchitis. Using a rapidly aging mouse model, the research team investigated whether the accumulation of age-related degenerative changes in the lung could be slowed by inhaled RSL. Treatment cohorts received either RSL or vehicle by intratracheal (IT) instillation monthly for three months. One month following the final treatment, whole lung function and injury-related gene expression in AEC2 were assessed. The research team found that inhaled, prophylactic resveratrol treatments can slow the rate of lung function decline, alveolar enlargement and alveolar epithelial type 2 cell DNA damage that occurs in the early stages of lung aging. They concluded that administration of resveratrol directly to the lungs may be an effective intervention for lung aging, which is a significant risk factor for development of chronic lung disease. "While the natural deterioration of the human lung generally occurs over decades, the injury to lung cells is analogous to the lung cell damage that occurs in premature infants who experience respiratory distress before their lungs have fully developed," added Driscoll. "Identifying a way to protect and strengthen young lungs before significant damage occurs is the goal of our research." Other contributors to the study include Sonia Navarro, Raghava Reddy, Jooeun Lee, and David Warburton, OBE, DSc, MD, of the Developmental Biology and Regenerative Medicine research program of The Saban Research Institute of Children's Hospital Los Angeles. The research was supported by NIH/NHLBI R01 HL65352, the Pasadena Guild Endowment, the Garland Fund, and NIH/NIDCR T90 training grant DE021982. Children's Hospital Los Angeles has been named the best children's hospital in California and among the top 10 in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll. Children's Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States. Children's Hospital is also one of America's premier teaching hospitals through its affiliation since 1932 with the Keck School of Medicine of the University of Southern California. For more information, visit CHLA.org. Follow us on Twitter, Facebook, YouTube and LinkedIn, or visit our blog at http://researchlablog. .
News Article | February 16, 2017
BRUSSELS, BELGIUM and WASHINGTON, DC--(Marketwired - Feb 16, 2017) - The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine and advanced therapies sector, today announced it has published its position on Hospital Exemption (HE) in response to vastly different interpretations and implementations across the European Union of Article 3(7) of Directive 2001/83/EC within article 28 (2) of the Advanced Therapy Medicinal Products (ATMP) Regulation. ARM believes that HE is a useful pathway to enable patients to receive an ATMP under controlled conditions in cases where no authorised medicinal product is available for an indication with a high unmet medical need. However, varying interpretations and implementations of HE among European Member States may lead to the supply of a medicine under HE when there is an existing licensed alternative that has undergone rigorous quality testing and demonstrated proven safety and efficacy. This undermines the case for investment in the licensing of ATMP, and as such, may act as a deterrent to developers and could ultimately limit the supply of products for European patients. "Throughout our efforts to advocate for the consistent interpretation and implementation of HE across the EU -- a topic that has been widely debated for several years -- we have been focused on understanding and defining an approach that will generate optimal outcomes for patients," said Jacqueline Barry, Chief Clinical Officer at Cell & Gene Therapy Catapult and chair of ARM EU Regulatory Committee. "This includes fostering a regulatory pathway for the development and widespread availability of innovative, disruptive medicines across the European community." In its position paper, ARM has outlined a series of proposals aimed at creating consistent implementation of HE across European Member States, including: "ARM has taken an important leadership role in advocating for a consistent interpretation and implementation of HE among European Union Member States," said Eduardo Bravo, Managing Director and CEO of TiGenix, member of the ARM Executive Committee. "We believe that ARM's initiative for greater clarity on HE addresses the hurdle to patients' access to effective treatments that the current divergent implementation of HE across the EU poses. Important for companies in our sector, clearly, is market access, and the position proposes a way forward to ensure HE is not misused to circumvent the applicable legal instruments for the authorisation of safe and effective medicinal products in Europe." ARM's official position on HE is available here. "We are very pleased that a series of planned activities, published by the EMA on 2nd February 2017 to foster ATMP development and enable expanded patient access in the EU, includes support of more transparency in HE, as proposed in our position paper. We encourage the stakeholders involved in the elaboration of the EU plan seeking to optimize the current regulatory framework to consider the other recommendations proposed in ARM's position on HE," concludes Annie Hubert, ARM's director of European public policy. About The Alliance for Regenerative Medicine The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine and advanced therapies worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Today, ARM has more than 250 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
News Article | February 21, 2017
Pain management doctor, Andrew Cottingham, MD of OPTIMAL Pain & Regenerative Medicine is the first physician in North Texas to implant the new Vertiflex Superion Indirect Decompression System®. The Vertiflex Superion is a minimally invasive, safe, out-patient procedure that gives patients an alternative to spine surgery for the treatment of lumbar spinal stenosis. Back and leg pain affects millions of Americans every year. Lumbar spinal stenosis is caused by aging and “wear” on the discs between the vertebrae. The degeneration of the discs causes the spinal canal to narrow, which leads to additional pressure on the nerves in the lower back. This pressure leads to lower back pain and radiating leg, buttock and/or groin pain. Symptoms typically intensify during standing and walking and decrease when sitting and bending forward. Conservative treatment of lumbar spinal stenosis typically involves rest, physical therapy, medication management and epidural steroid injections. When non-surgical treatment does not alleviate symptoms, surgical treatment historically involves direct compression surgery. The Vertiflex Superion device is an FDA approved minimally invasive treatment option for patients suffering from lower back pain and radiating leg pain caused by lumbar spinal stenosis. The procedure uses a Superion implant, which is a small titanium device that is inserted through a small incision in the lower back. The implant is then placed in the spinal structure to keep the spine positioned such that the nerves in the spinal canal are not compressed. The device has been implanted in more than 2,000 patients worldwide. The clinical trial results showed a decrease in pain. Four years post-procedure, almost 90% of the clinical trial patients expressed continuing satisfactory results. "The Vertiflex Superion is an elegant, minimally invasive procedure that can change so many people's lives who are suffering from lower back pain and radiating leg pain caused by lumbar spinal stenosis," said Dr. Andrew Cottingham. To learn if you are a candidate, please call us at 817-468-4343 or visit our website: The Vertiflex Superion Procedure. The pain management doctors at OPTIMAL, Drs. Cottingham, Berlin and Phillips, are dedicated to staying on the forefront of pain management and regenerative medicine procedures. Each physician is double-board certified in anesthesiology and pain medicine. Through their collective expertise, the OPTIMAL team delivers comprehensive, current and compassionate medical care to patients in Dallas, Fort Worth and Arlington, Texas.
News Article | February 27, 2017
Scientists at Rutgers and other universities have created a new way to identify the state and fate of stem cells earlier than previously possible. Understanding a stem cell's fate -- the type of cell it will eventually become -- and how far along it is in the process of development can help scientists better manipulate cells for stem cell therapy. The beauty of the method is its simplicity and versatility, said Prabhas V. Moghe, distinguished professor of biomedical engineering and chemical and biochemical engineering at Rutgers and senior author of a study published recently in the journal Scientific Reports. "It will usher in the next wave of studies and findings," he added. Existing approaches to assess the states of stem cells look at the overall population of cells but aren't specific enough to identify individual cells' fates. But when implanting stem cells (during a bone marrow transplant following cancer treatment, for example), knowing that each cell will become the desired cell type is essential. Furthermore, many protein markers used to distinguish cell types don't show up until after the cell has transitioned, which can be too late for some applications. To identify earlier signals of a stem cell's fate, an interdisciplinary team from multiple universities collaborated to use super-resolution microscopy to analyze epigenetic modifications. Epigenetic modifications change how DNA is wrapped up within the nucleus, allowing different genes to be expressed. Some modifications signal that a stem cell is transitioning into a particular type of cell, such as a blood, bone or fat cell. Using the new method, the team of scientists was able to determine a cell's fate days before other techniques. "Having the ability to visualize a stem cell's future will take some of the questions out of using stem cells to help regenerate tissue and treat diseases," says Rosemarie Hunziker, program director for Tissue Engineering and Regenerative Medicine at the National Institute of Biomedical Imaging and Bioengineering. "It's a relatively simple way to get a jump on determining the right cells to use." The approach, called EDICTS (Epi-mark Descriptor Imaging of Cell Transitional States), involves labeling epigenetic modifications and then imaging the cells with super resolution to see the precise location of the marks. "We're able to demarcate and catch changes in these cells that are actually not distinguished by established techniques such as mass spectrometry," Moghe said. He described the method as "fingerprinting the guts of the cell," and the results are quantifiable descriptors of each cell's organization (for example, how particular modifications are distributed throughout the nuclei). The team demonstrated the method's capabilities by measuring two types of epigenetic modifications in the nuclei of human stem cells cultured in a dish. They added chemicals that coaxed some of the cells to become fat cells and others to become bone, while another set served as control. Within three days, the localization of the modifications varied in cells destined for different fates, two to four days before traditional methods could identify such differences between the cells. The technique had the specificity to look at regional changes within individual cells, while existing techniques can only measure total levels of modifications among the entire population of cells. "The levels are not significantly different, but how they're organized is different and that seems to correlate with the fact that these cells are actually exhibiting different fates," Moghe said. "It allows us to take out a single cell from a population of dissimilar cells," which can help researchers select particular cells for different stem cell applications. The method is as easy as labeling, staining and imaging cells - techniques already familiar to many researchers, he said. As the microscopes capable of super resolution imaging become more widely available, scientists can use it to sort and screen different types of cells, understand how a particular drug may disrupt epigenetic signaling, or ensure that stem cells to be implanted won't transform into the wrong cell type.
News Article | February 15, 2017
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Regenerative Medicine Market - Forecast to 2021" report to their offering. The global Regenerative medicine market is expected to reach USD 38.70 Billion by 2021 from USD 13.41 Billion in 2016 at a CAGR of 23.6% from 2016 to 2021. The major factor driving the growth of regenerative medicine market, are government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in global healthcare expenditure, and rapid growth in the aging population. The global Regenerative medicine market is segmented based on type, therapy, application, and regions. The cell-based products segment is expected to register to have largest market share in the Regenerative medicine market, by type, during the forecast period. The high growth in this segment is attributed to the increasing awareness about stem cell therapy, growing funding for new stem cell lines, and development of advanced genomic methods. On the basis of therapy, the cell therapy procedure is expected to account for the largest share of the market in 2016. Increasing funding from several agencies and private organizations for the research and development of cell therapies, growing inclination of the healthcare industry towards stem cell research, and increasing global awareness about the benefits of stem cell therapies will drive the growth of this market. On the basis of applications, the segments are orthopedic & musculoskeletal disorders, dermatology, cardiology, diabetes, central nervous system diseases, and other applications. Oncology is the fastest growing application market. Increasing cancer incidence, rich product pipeline and increasing demand for cancer treatments fueling the growth of the market. For more information about this report visit http://www.researchandmarkets.com/research/jf9pj5/regenerative
News Article | February 17, 2017
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Regenerative Medicine - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Regenerative Medicine in US$ Million. The report profiles 52 companies including many key and niche players such as For more information about this report visit http://www.researchandmarkets.com/research/8n66f5/regenerative
News Article | February 16, 2017
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Regenerative Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts" report to their offering. The Global Regenerative Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2010. The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals. The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. In Global Regenerative Medicine Partnering 2010-2017: Deal trends, players, financials and forecasts, the available deals are listed by: For more information about this report visit http://www.researchandmarkets.com/research/5f5sqc/global
News Article | February 15, 2017
Global Regenerative Medicine Market Assessment Report Now Available at Credence Research New Market Research Reports Title "Global Regenerative Medicine Market Assessment Report Now Available at Credence Research" Has Been Added to Credenceresearch.com Report Database. San Jose, CA, February 15, 2017 --( Browse the report at http://www.credenceresearch.com/report/regenerative-medicine-market Based on geographic/regional distribution the global Regenerative Medicine Market is studied for key regional markets focusing on the respective geographic trends and statistics, and thereby delivering market size and forecast values. The Regenerative Medicine Market based on geographic classification is studied for North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa markets. Among these, the North America, Europe and Asia-Pacific Regenerative Medicine Market is studied for top country-level markets. The Regenerative Medicine industry in each individual country market is studied based on parameters such as per capita income, population, gross domestic product (GDP), status of infrastructure, purchasing power parity, etc. Technology development, industry concentration, end-user preference, and similar such grounds are also considered while estimating the market for Regenerative Medicine. The market estimates are provided for the period 2014-2022, along with corresponding compounded annual growth rates (CAGRs) for the forecast period 2016-2022. Request Table of content - http://www.credenceresearch.com/request-table-of-content/58213 This report on Regenerative Medicine Market also offers competition assessment tools such as market positioning of key players, attractive investment proposition, and Porter’s Five Forces model to give the readers a view of the competitive scenario of the Regenerative Medicine Market. The Regenerative Medicine Market report is concluded with company profiles chapter. This section highlights major information about the key players engaged in development, manufacture, distribution and sale of Regenerative Medicine in the international markets. Request free sample - http://www.credenceresearch.com/sample-request/58213 Major extracts from the Table of Content of Regenerative Medicine Market, 2016-2022 report: Regenerative Medicine Market Dynamics – Drivers, Challenges, Opportunities Regenerative Medicine Market Size and Forecast for the Period 2014-2022 Regenerative Medicine Market CAGR for the Period 2016-2022 Regenerative Medicine Market Competitive Analysis, by Key Players Regenerative Medicine Market: Attractive Investment Proposition, by Geography Regenerative Medicine Market: Key Commercial Events Regenerative Medicine Market: Future Prospects (upcoming product approvals) About Us: Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task. Who we are Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals. Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa. Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect. What we do We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability. No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies. Media Contact Name: Chris Smith (Global Sales Manager) Address: 105 N 1st ST #429, San Jose, CA 95103 US E-mail: email@example.com Ph: 1-800-361-8290 Web: http://www.credenceresearch.com San Jose, CA, February 15, 2017 --( PR.com )-- Credence Research has recently issued a new market assessment report titled “Regenerative Medicine – Growth, Future Prospects and Competitive Analysis, 2016 – 2022.” The global Regenerative Medicine Market study provides a comprehensive view of the ongoing and future phases of the Regenerative Medicine industry based on parameters such as major commercial events, research initiatives, government guidelines, market drivers, restraints and opportunities and detailed industry segmentation and regional distribution.Browse the report at http://www.credenceresearch.com/report/regenerative-medicine-marketBased on geographic/regional distribution the global Regenerative Medicine Market is studied for key regional markets focusing on the respective geographic trends and statistics, and thereby delivering market size and forecast values. The Regenerative Medicine Market based on geographic classification is studied for North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa markets. Among these, the North America, Europe and Asia-Pacific Regenerative Medicine Market is studied for top country-level markets. The Regenerative Medicine industry in each individual country market is studied based on parameters such as per capita income, population, gross domestic product (GDP), status of infrastructure, purchasing power parity, etc. Technology development, industry concentration, end-user preference, and similar such grounds are also considered while estimating the market for Regenerative Medicine. The market estimates are provided for the period 2014-2022, along with corresponding compounded annual growth rates (CAGRs) for the forecast period 2016-2022.Request Table of content - http://www.credenceresearch.com/request-table-of-content/58213This report on Regenerative Medicine Market also offers competition assessment tools such as market positioning of key players, attractive investment proposition, and Porter’s Five Forces model to give the readers a view of the competitive scenario of the Regenerative Medicine Market. The Regenerative Medicine Market report is concluded with company profiles chapter. This section highlights major information about the key players engaged in development, manufacture, distribution and sale of Regenerative Medicine in the international markets.Request free sample - http://www.credenceresearch.com/sample-request/58213Major extracts from the Table of Content of Regenerative Medicine Market, 2016-2022 report:Regenerative Medicine Market Dynamics – Drivers, Challenges, OpportunitiesRegenerative Medicine Market Size and Forecast for the Period 2014-2022Regenerative Medicine Market CAGR for the Period 2016-2022Regenerative Medicine Market Competitive Analysis, by Key PlayersRegenerative Medicine Market: Attractive Investment Proposition, by GeographyRegenerative Medicine Market: Key Commercial EventsRegenerative Medicine Market: Future Prospects (upcoming product approvals)About Us:Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.Who we areCredence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.What we doWe serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.Media ContactName: Chris Smith (Global Sales Manager)Address: 105 N 1st ST #429, San Jose, CA 95103 USE-mail: firstname.lastname@example.orgPh: 1-800-361-8290Web: http://www.credenceresearch.com Click here to view the list of recent Press Releases from Credence Research